NCT06277219 - A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1) | Biotech Hunter

Enrollment

150

Participants

Timeline

Start Date

June 5, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

March 31, 2027

Conditions

Advanced Solid Tumor

Interventions

DRUG

LAT010

LAT010 monotherapy

DRUG

LAT010 + ICI

LAT010 combination with PD-1 inhibitor

Trial Locations (4)

COMPLETED

D&H Cancer Research Center, Margate

TERMINATED

Huntsman Cancer Institute, Salt Lake City

RECRUITING

Cancer Hospital of Shandong First Medical University, Jinan

RECRUITING

The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou